|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q3 FY2013
As of Sep 30, 2013
|
Q2 FY2013
As of Jun 30, 2013
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Current assets | |||||||||||||||||||
| Cash and Cash equivalents | |||||||||||||||||||
| Accounts receivable | |||||||||||||||||||
| Inventories (Note 3) | |||||||||||||||||||
| Inventories (Note 4) | |||||||||||||||||||
| Prepaid expenses and deposits | |||||||||||||||||||
| Valued added tax, income taxes and other receivables | |||||||||||||||||||
| Restricted cash (Note 13) | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Property and equipment, net (Note 5) | |||||||||||||||||||
| Investment in equity method and cost investments (Note 3) | |||||||||||||||||||
| Intangible assets, net (Note 6) | |||||||||||||||||||
| Goodwill | |||||||||||||||||||
| Restricted cash | |||||||||||||||||||
| Deferred financing costs | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| Liabilities | |||||||||||||||||||
| Current liabilities | |||||||||||||||||||
| Accounts payable and accrued liabilities (Note 7) | |||||||||||||||||||
| Income taxes payable (Note 14) | |||||||||||||||||||
| Deferred revenue | |||||||||||||||||||
| Deferred grants (Note 9) | |||||||||||||||||||
| Warrants financial liability (Note 13) | |||||||||||||||||||
| Short-term portion of long-term debt (Note 8) | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Long-term debt (Note 8) | |||||||||||||||||||
| Warrants financial liability (Note 13) | |||||||||||||||||||
| Other long-term liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Redeemable non-controlling interest (Note 12) | |||||||||||||||||||
| Equity | |||||||||||||||||||
| Common stock: $0.01 par value per share; 250,000,000 authorized, 52,114,923 and 30,612,733 issued and outstanding at December 31, 2017 and December 31, 2016, respectively | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Warrants | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||||
| Total BioAmber Inc. shareholders’ equity | |||||||||||||||||||
| Total equity | |||||||||||||||||||
| Total liabilities and equity | |||||||||||||||||||
Loading...
